|Bid||41.85 x 4000|
|Ask||0.00 x 800|
|Day's range||41.55 - 42.21|
|52-week range||35.32 - 46.47|
|Beta (3Y monthly)||0.54|
|PE ratio (TTM)||21.57|
|Earnings date||29 Jul 2019 - 2 Aug 2019|
|Forward dividend & yield||1.44 (3.55%)|
|1y target est||45.00|
People using e-cigarettes to quit smoking are about 95% more likely to report success than those trying to quit without help from any stop-smoking aids, according to the results of a large study in England. The research, funded by the charity Cancer Research UK and published in the journal Addiction on Thursday, analyzed success rates of several common stop-smoking methods - including e-cigarettes, nicotine replacement therapy (NRT) patches and gum, and Pfizer's varenicline, sold as Champix in the UK. It also adjusted for a wide range of factors that might influence success rates for quitting - such as age, social level, degree of cigarette addiction, previous attempts to quit, and whether quitting was gradual or abrupt.
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.
Pfizer Inc. (PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
SAN FRANCISCO/NEW YORK, May 13 (Reuters) - Three years ago, the beginning of the end of the U.S. television business looked certain when one of the largest ad buying agencies vowed to move a big chunk of its purchases to YouTube from TV budgets. Instead, data compiled by ad tracking firm MediaRadar at Reuters' request shows some advertisers are spending more on television networks' online properties and less on Alphabet Inc's video service. The data may partially explain why Google's parent had its slowest quarterly revenue growth in three years.
Shares in generic drugmakers including Teva, Mylan, Novartis, Sandoz, and Pfizer fell on Monday after 44 US states announced a lawsuit alleging an anti-competitive conspiracy to artificially inflate prices for more than 100 drugs, some by more than 1,000 per cent. Teva shares were down 11 per cent at $12.75, Mylan lost 6 per cent to $20.73, Novartis declined 2 per cent to $80.27 and Pfizer was 1 per cent lower at $40.35 on Monday, amid fears that the drugmakers could be hit with damages and penalties as a result of the suit, which was filed on Friday.
Despite competition from other drugmakers, Pfizer has been able to maintain a significant share in the erectile dysfunction market thanks in part to launching its own generic version of the blue, diamond-shaped pill.
Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
London's main index jumped as investors held out for a resolution to the Sino-U.S. trade dispute even as higher U.S. tariffs on more Chinese goods took effect, and airline group IAG rose after in-line first-quarter results. The FTSE 100 was up 0.5% and the FTSE 250 was up 0.6% by 0725 GMT, ahead of GDP data.